A study of efficacy and safety of 5-aminolevulinic acid phosphate in patients with sideroblastic anemia

A study of efficacy and safety of 5-aminolevulinic acid phosphate in patients with sideroblastic anemia - Efficacy and safety of 5-ALA phosphate in patients with sideroblastic anemia

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000021407

Enrollment

Registered

2016-03-15

Start date

2016-03-15

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

sideroblastic anemia

Interventions

Orally intake a 150 mg 5-aminolevulinic acid phosphate capsule once a day for up to 24 weeks.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Individuals with sideroblastic anemia willing to give written informed consent for study participation

Exclusion criteria

Exclusion criteria: Platelet count less than 100,000/micro L. Neutrophil count less than 1500/micro L.

Design outcomes

Primary

Measure	Time frame
Efficacy (improvement of the hemoglobin value) at 12 weeks after the initiation of the treatment.	—

Secondary

Measure	Time frame
Safety until 8 weeks after the discontinuation of the treatment.	—

Countries

Japan

Contacts

Public ContactHiroshi Kawabata

Graduate School of Medicine, Kyoto University Department of Hematology and Oncology

hkawabat@kuhp.kyoto-u.ac.jp075-751-4964

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026